

REMARKS/ARGUMENTS

After amendment, the pending claims are 22, 25, 26, 29-32, 37, 38, 41-47, 49, and 51-74. Claims 37 and 38 are amended to place the application in condition for allowance. No new matter is added by these amendments.

Claims 1, 2, 4-20, 48, and 50 are canceled in an effort to place the application in condition for allowance. Applicants reserve the right to prosecute these claims in a continuation application filed during the pendency of the present application.

New claims 51-74 parallel allowable claims 22, 25, 26, and 30-32 and depend directly or indirectly from independent claims 37, 38, 41, 45, and 49. Support for these claims is found in the original specification. No new matter is added by these new claims.

35 USC § 112, First Paragraph Rejection

The Examiner rejected claims 37 and 38 under 35 USC § 112, first paragraph.

The Examiner asserted that "...the ability to reduce blood glucose levels or delay the onset of increasing glucose levels is not representative of the ability to prevent any increase in glucose levels in an animal following administration of antisense that targets and inhibits the expression of PTP1B".

Applicants respectfully request reconsideration and withdrawal of this rejection for the following reason.

In an effort to place the application in condition for allowance, Applicants have amended claims 37 and 38 by deleting the objected term "preventing".

Reconsideration of this objection is requested.

35 USC § 103(a) Rejection

The Examiner rejected claims 1, 2, 4-20, 48, and 50 under 35 USC § 103(a) over the combined teachings of Huang et al. (Huang et al 1998 *FASEB J.*, 12(4):A188, Abstract 1099), Olefsky (US Patent No. 5,726,027), Chernoff et al. (1990, *PNAS, USA*, 87:2735-2739), Milner et al. (Milner et al, 1997 *Nature*, 15:537-541), and Baracchini et al. (US Patent No. 5,801,154).

The cancellation of claims 1, 2, 4-20, 48, and 50 moots the outstanding rejection.

Supplemental Information Disclosure Statement

Applicants have enclosed herewith a Fourth Supplemental Information Disclosure Statement and request consideration of the documents cited therein. Applicants note that the documents therein were cited in recently issued European search report.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200